chevron_rightThe maternal serum screening test is a blood test offered to pregnant women.
chevron_rightThe test may be performed at around 10 weeks (combined first-trimester screening test or double marker) or between 14 and
20 weeks (second-trimester maternal serum screening test or quadruple marker).
chevron_rightIt is a prenatal screening test using blood from the mother that can help identify women who may be carrying a baby with certain types of birth defects (such as neural tube defects, Down syndrome, Patau syndrome, and trisomy 18 syndrome).
chevron_rightThis test measures levels of proteins produced by the fetus or placenta.
chevron_rightIt measures levels of PP13, sFlt-1 and FSLT3, which play an important role in predicting late-onset preeclampsia, and the combination of these three markers significantly increases the detection rate for prediction.
chevron_rightIt is a compulsory screening test for all the pregnant women.
chevron_rightMaternal marker screening has advanced rapidly since AFP was first used to screen for NTDs. There are now a range of high performance tests available to screen for chromosomal abnormalities suiting localities with different financial restraints and availability of quality ultrasound.
Different types of Maternal serum markers are available in Sandor.
chevron_rightQuadruple Marker Beta hCG + AFP + uE3 + Inhibin A hormone value.
The results are combined with the womans age risk to give a final chance of Down syndrome, Edward syndrome
or neural tube defects. The result is reported as an increased chance or low-chance result.
chevron_rightA modern fluorescent based immunoassay (Immunofluorometry method) uses as the detection reagent a fluorescent compound which absorbs light or energy (excitation energy) at a specific wavelength and then emits light or energy at a different wavelength.
chevron_rightA Screening tests do not give definitive prenatal diagnosis, but do provide a risk/probability of a problem.
If Positive Screening Test, Then further tests are :